Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. - Wikidata - awgldk - TriplyDB

Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer.

Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer.

http://www.wikidata.org/entity/Q52838313

about

Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?Implications of High Rates of Metastatic Prostate Cancer in BRCA2 Mutation Carriers BRCA1 missense polymorphisms are associated with poor prognosis of pancreatic cancer patients in a Chinese population.Screening for familial and hereditary prostate cancer.A cohort analysis of men with a family history of BRCA1/2 and Lynch mutations for prostate cancer BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer.Biallelic BRCA2 Mutations Shape the Somatic Mutational Landscape of Aggressive Prostate Tumors Biomarkers for prostate cancer: present challenges and future opportunities.Germline genetic profiling in prostate cancer: latest developments and potential clinical applications.Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories.Racial Disparity in Prostate Cancer-Specific Mortality for High-Risk Prostate Cancer: A Population-Based Study.Germline genetic variants in men with prostate cancer and one or more additional cancers.Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer.Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting.Genetic predisposition to prostate cancer.Screening Men at Increased Risk for Prostate Cancer Diagnosis: Model Estimates of Benefits and Harms.Treatment strategies for DNA repair-deficient prostate cancer.Common variation in BRCA1 may have a role in progression to lethal prostate cancer after radiation treatment Acquiring evidence for precision prostate cancer care.Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer Gene-expression profiling of localized prostate cancer: still miles to go before we sleep.Germline BRCA mutation in male carriers-ripe for precision oncology?BRCA1/2 Mutations in Salivary Pleomorphic Adenoma and Carcinoma-ex-Pleomorphic Adenoma.The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer.A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.Immunotherapy for Prostate Cancer: Where We Are Headed.A review of prostate cancer genome wide association studies (GWAS).Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.Clinical and pathologic factors predicting reclassification in active surveillance cohorts.Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.Incorporating Biomarker Stratification into STAMPEDE: an Adaptive Multi-arm, Multi-stage Trial Platform.Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer.PARP inhibitors for homologous recombination-deficient prostate cancer.Prostate cancer screening-when to start and how to screen?A novel BRCA2 mutation in prostate cancer sensitive to combined radiotherapy and androgen deprivation therapy.Somatic BRCA2 bi-allelic loss in the primary prostate cancer was associated to objective response to PARPi in a sporadic CRPC patient.Male Oncology Research and Education program for men at high risk for prostate cancer.Aberrations of DNA Repair Pathways in Prostate Cancer: Future Implications for Clinical Practice?Rare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease

P2860

Q28073673-7F67BCD4-0D55-4F07-837E-2EFCE7AADA42 Q33796352-97B057D5-BE57-4478-83FE-56F0B021DC1C Q33829394-A471144E-2C8C-4728-89EA-D4886EAB1860 Q35861576-36E79D2D-7C06-4354-B6A1-223F179BF655 Q36085161-CAAF71E2-3255-4825-A6F2-F3E2F1EE072C Q36347042-61600139-6E66-462A-B745-AD8D561FF223 Q36891144-BE15CB9B-CA47-4745-B8F0-A7B098A272D6 Q37474443-B9EBED76-ADDA-4739-AD30-437B6D143C7F Q37474516-BFB2D14A-F872-4880-B35E-6F6B501C44E3 Q37581351-2FE0D86A-A967-468F-BE38-83839815B2C6 Q37624321-61D862E8-535E-4645-85EF-98E757ABA6BA Q38705089-E55DB9DA-17FD-4D89-B224-C95C5BF57384 Q38893354-F2470D97-39D4-43C2-8031-81267CFFFDB0 Q38966736-6B43AA47-8244-4B2B-991B-A4F0A66B22E1 Q39035687-B1D8115D-1181-4919-ABBF-DEB0D917B5F8 Q39289771-8319CE32-7D9F-4246-BF41-9116D5CC9D81 Q39345771-A801200E-A73A-4486-A4BA-8F97147C9849 Q40880573-7DF04CF0-4A88-4263-A8D4-97FF55E46BF9 Q42290401-2F2229E5-A10C-4676-978E-34938721A96D Q42704874-3C6BFDE3-2580-4CF5-9BF5-8E7397AD7E24 Q44062050-AE7871B1-A269-43AB-A93C-9E26BE93C60C Q46798905-BD9A9165-A209-4508-A4CA-4F8858F8B409 Q47101613-60A9805C-71BC-49E2-98F3-66683FC655B3 Q47347786-B7B376F0-4B72-4924-8B39-E31CF3F8A66E Q47953839-82445C0C-254D-46BE-A8D5-7B3043F62A2F Q48176349-586895B0-4310-4681-B104-819531900722 Q48515655-4C82640E-246A-4312-9EEF-28714E2812B5 Q49340500-43FE9042-06D7-46FC-A72E-9000B6943F73 Q49715354-5804E660-C707-46E2-B969-27DB894243FE Q50030814-B86E7C87-179B-41B1-B731-E8FC0130421C Q50099775-A3D75F79-767E-47EE-91B9-1D7403513B49 Q51003983-B999D6E5-AFCD-4B6E-8F3A-1F436E99FAB4 Q51465026-EB3F62A6-2748-4792-B491-173931B0D530 Q52623144-2683E438-5D91-4957-982C-5D9C09FC5297 Q52624230-3C8D2BF9-027E-477D-9171-6CD39A939E6F Q52630405-95AD960E-3D95-416F-B7C3-FAB1830822F8 Q53742127-91D8C18A-B62D-4B37-8A7B-7C458A0AC55A Q55249860-73A833C7-3B70-4A6C-B8E4-F083FEF65D35 Q57106332-869D8C97-B5DC-43B9-A1F5-70DA382E0BFE Q57177774-3ABB1A1B-0BB9-4CC0-A03B-94660E2B22E6

P2860

Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer.

http://www.wikidata.org/entity/Q52838313

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Effect of BRCA Mutations on Me ...... for Localised Prostate Cancer.

@en

Effect of BRCA Mutations on Me ...... for Localised Prostate Cancer.

@en-gb

Effect of BRCA Mutations on Me ...... for Localised Prostate Cancer.

@nl

type

label

Effect of BRCA Mutations on Me ...... for Localised Prostate Cancer.

@en

Effect of BRCA Mutations on Me ...... for Localised Prostate Cancer.

@en-gb

Effect of BRCA Mutations on Me ...... for Localised Prostate Cancer.

@nl

prefLabel

Effect of BRCA Mutations on Me ...... for Localised Prostate Cancer.

@en

Effect of BRCA Mutations on Me ...... for Localised Prostate Cancer.

@en-gb

Effect of BRCA Mutations on Me ...... for Localised Prostate Cancer.

@nl

P1433

Q52838313-4032F26A-798D-4A46-8167-19818A8DD3AD

P1476

Q52838313-DD51695F-09D0-4189-90DA-89612671FA12

P2093

Q52838313-06E7A14C-D684-4BCE-9666-CB56480F6323

Q52838313-11F6C6F9-C7A6-4F63-A431-A52249D7736E

Q52838313-14D10A3A-8724-4865-9DA8-ADF5ACDCF1AF

Q52838313-1625BB42-FEF2-4DD3-96E0-ABAE26691673

Q52838313-21D3EC00-76FA-48AD-A3F6-5E2ADD947984

Q52838313-290E3698-8D8E-4782-8541-040AB7E7C1F5

Q52838313-45BB8D43-A5CA-48F0-8A66-944B74D9C008

Q52838313-51C172D2-F9CF-42D5-9EA7-7B26F01725B4

Q52838313-638A1AEA-6238-4291-9415-895E473E47E5

Q52838313-779A394F-6179-4483-BD8D-16F2654EBC54

P304

Q52838313-4FCD435F-89B7-4DF2-B9E6-D9D45F82EC72

P31

Q52838313-4EC6C005-7CE4-450C-A3B6-8EDE2E75FF41

P356

Q52838313-428A4FC1-51EA-44A3-909B-6D3BD3A12E02

P407

Q52838313-BDC66E4B-FCA8-41F0-833A-4BB27C004796

P433

Q52838313-17E0AF29-1A22-4763-804C-980181E03A5A

P478

Q52838313-9B3FCF31-3F1F-4CB5-B04D-BE10C1D4DA3D

P50

Q52838313-264D15F4-4213-440F-88E2-98E7B386C0A8

Q52838313-2D1BE8BB-5BBB-427B-AAE0-AABA0EDFF8FF

Q52838313-6CC57D2D-8538-4412-A054-39E44B0099DE

Q52838313-8482E2F2-D334-4FEA-9C4D-040E9E787531

Q52838313-8C397BEE-5670-48FA-96A7-5F778CB790C4

Q52838313-9448CE14-7377-4314-93B0-A28315B85C4F

Q52838313-CAC0B259-0224-497E-B4BE-6A4DE6798F55

Q52838313-D9B9F626-3D74-4D18-A698-503ED4A427A5

Q52838313-E062E31B-C4BC-4A66-A11D-B1C9B9571974

Q52838313-E913C75D-C132-4B3B-A49C-479AD47C7DC3

P577

Q52838313-E32BC9C3-60B9-48E3-A093-8DF898436302

P5875

Q52838313-4555DB80-0DB2-4FF9-86FD-E66EC525CF24

P698

Q52838313-12CC18CE-3BBC-409F-8175-09C882055220

P356

J.EURURO.2014.10.022

P1433

European Urology

P1476

Effect of BRCA Mutations on Me ...... for Localised Prostate Cancer.

@en

P2093

Alan Donaldson

http://www.w3.org/2001/XMLSchema#string

Carole Brewer

http://www.w3.org/2001/XMLSchema#string

Chee Goh

http://www.w3.org/2001/XMLSchema#string

David Olmos

http://www.w3.org/2001/XMLSchema#string

Ed Saunders

http://www.w3.org/2001/XMLSchema#string

Elizabeth Bancroft

http://www.w3.org/2001/XMLSchema#string

Fiona Douglas

http://www.w3.org/2001/XMLSchema#string

Jacqueline Eason

http://www.w3.org/2001/XMLSchema#string

Koveela Govindasami

http://www.w3.org/2001/XMLSchema#string

M John Kennedy

http://www.w3.org/2001/XMLSchema#string

P304

186-193

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EURURO.2014.10.022

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

68

http://www.w3.org/2001/XMLSchema#string

P50

Zsofia Kote-Jarai

Daniel Leongamornlert

Julian Weldon Adlard

Douglas F. Easton

Antonis C Antoniou

P577

2014-11-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

269171315

http://www.w3.org/2001/XMLSchema#string

P698

25454609

http://www.w3.org/2001/XMLSchema#string